ONCTERNAL THERAPEUTICS INC (ONCT)
US68236P2065 - Common Stock
ONCTERNAL THERAPEUTICS INC
NASDAQ:ONCT (11/25/2024, 5:52:41 PM)
After market: 0.76 +0.05 (+7.04%)0.71
-0.43 (-37.72%)
Company Profile
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
Company Info
ONCTERNAL THERAPEUTICS INC
12230 El Camino Real, Suite 230
San Diego CALIFORNIA 92130
P: 18584341113
CEO: James B. Breitmeyer
Employees: 29
Website: https://www.oncternal.com/
ONCT News
2 hours ago - ChartmillWhat's going on in today's after hours sessionCurious about the stocks that are showing activity after the closing bell on Monday?
4 hours ago - ChartmillLet's take a look at the stocks that are in motion in today's session.Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
6 hours ago - ChartmillLet's take a look at the stocks that are in motion in today's session.Top movers analysis in the middle of the day on 2024-11-25: top gainers and losers in today's session.
8 hours ago - ChartmillThe market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.Which stocks are gapping on Monday?
10 hours ago - ChartmillWhich stocks are moving before the opening bell on Monday?As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
a month ago - Oncternal TherapeuticsOncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerSAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced updated data from its Phase 1/2...
ONCT Twits
Here you can normally see the latest stock twits on ONCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
